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Background: Hepatitis B virus (HBV) is a common cause of liver disease throughout the world. HBV is transmitted
through blood and other body fluids, including semen and saliva. Chronic replication of HBV virons is characterized
by persistence circulation of HBsAg, HBeAg and HBV DNA; usually with anti-HBc and occasionally with anti-HBs. Aim:
To determine the prevalence of HBeAg, IgG anti-HBcore and IgM anti-HBcore amongst HBsAg positive blood
donors. These parameters are reflective of transmissibility and active hepatitis B infection. A cross sectional study
was carried out at the blood donor clinics of Lagos State University Teaching Hospital Ikeja and Lagos University
Teaching Hospital Idiaraba. A total of 267 donors were recruited to determine HBe antigen, IgG and IgM anti-
HBcore antibodies amongst hepatitis BsAg positive donors. Five milliliters of blood was collected from those who
tested positive to HBsAg screen during donation. The sera were subjected to enzyme linked immunosorbent assay
(ELISA). Pearson chi-squared test was used for the analytical assessment.
Findings: A total number of 267 HBsAg positive blood donors were studied. A seroprevalence of 8.2% (22 of 267)
HBeAg was obtained, 4 of 267 (1.5%) were indeterminate while 241 (90.3%) tested negative. Only 27 out of 267 donors
(10.1%) tested positive to IgM anti-HBcore, 234(87.6%) tested negative, while 6(2.2%) were indeterminate. A higher
percentage of 60.7% (162 of 267) tested positive to IgG anti-HBcore, while 39.3% (105 of 267) tested negative.
Conclusion: There is a low seroprevalence rate of HBeAg-positive chronic hepatitis and relatively high IgG anti-HBcore
and IgM anti-HBcore rates in South West Nigeria.
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Hepatitis B virus (HBV) is a common cause of liver disease
throughout the world. Cirrhosis, liver failure and hepatocel-
lular carcinoma develop in 15–40% of chronically infected
hepatitis B virus individuals [1]. HBV is transmitted through
blood and other body fluids, including semen and saliva.
The virus is hundred times more infectious than human* Correspondence: ajoke_clinic@yahoo.co.uk
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medium, provided the original work is properlyimmunodeficiency virus (HIV) and unlike HIV; it can live
outside the body in dried blood for longer than a week [2].
It may present as acute hepatitis with resolution or
chronic hepatitis which may evolve to cirrhosis and ful-
minant hepatitis with massive liver necrosis and the
backdrop for hepatitis D virus infection. Chronic HBV
infection is defined as hepatitis B surface antigen
(HBsAg) positivity for at least six months [3]. Over 350
million of the 2 billion individuals infected with hepatitis
B virus worldwide are chronically infected [4]. An esti-
mated one third of the world’s population has serological Ltd. This is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
cited.
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than one million deaths annually [5].
HBV infection occurs frequently in Nigeria [6,7]. It is
estimated that about 12% of the total Nigerian popula-
tion of 140 million is chronically infected with Hepatitis
B virus [8,9].
The global prevalence of chronic hepatitis B infection
varies widely, from >8% in Africa, Asia, and the Western
Pacific to 2–7% in Southern and Eastern Europe, and
to <2% in Western Europe, North America, and Australia.
In the United States of America, an estimated 185,000 new
infections evolved yearly [10].
Studies from different parts of Nigeria have reported
varying prevalence rates among blood donors. A preva-
lence rate of 5.1% was found in blood donors in Ibadan,
West [11], 11.4% in Zaria, North [12], 10.4% in Benin,
South [13], 3.7% in Enugu, East [14], and 1.57% in Port
Harcourt South [15]. Patients with chronic hepatitis repre-
sent carriers of actively replicating virus and hence are
sources of infection to other individuals [16]. HBV also
plays an important role in the development of hepatocellu-
lar carcinoma. The presence of only HBsAg neither indi-
cates replication nor infectivity [17]. On the contrary,
chronic replication of HBV virons is characterized by per-
sistence circulation of HBsAg, HBeAg and HBV DNA;
usually with anti-HBc and occasionally with anti-HBs [17],
which may result to progressive liver damage in these
patients [17]. The objective of this study was to determine
the prevalence of HBeAg, IgG anti-HBcore and IgM anti-
HBcore amongst HBsAg positive blood donors.
Although there is abundant data on the seropreva-
lence of HBsAg in Nigeria, there is need for more infor-
mation on the seroprevalence of HBeAg, an indicator of
hepatitis B virus transmissibility and HBcore antibodies
which when present, indicates likely progression to liver
cirrhosis, fulminant hepatitis and primary liver cell car-
cinoma. It is therefore important to study not only the
seroprevalence of HBsAg amongst blood donors, but
also to determine HBeAg and HBcore antibodies which




A cross sectional study was carried out at the blood
donor clinics of Lagos State University Teaching Hospital
Ikeja (LASUTH) and Lagos University Teaching Hospital
Idiaraba (LUTH) between January 2010 and June 2011.
Consent was obtained from each prospective blood donor
recruited into the study and approval was obtained from
both institutions’ Research and Ethics Committees. Partici-
pants completed structured questionnaires which included
demographic information, previous history of blood trans-
fusion, number of sexual partners, type of donor, history ofunprotected sex, and use of intravenous drug. Assistance
was rendered where necessary.
Inclusion criteria
HBsAg positivity and all who met the criteria as blood
donors i.e. age between 18–65 years, blood pressure
<140/90 mmHg, pulse< 100 BPM, no blood donation
in the last 3 months, no chronic illnesses such as dia-
betes mellitus, asthma, or history of allergy.
Exclusion criteria
Those who did not meet the criteria for blood donation
stated in the inclusion criteria and HBsAg negative
donors.
Collection of samples
Blood samples of 5 ml were collected from HBsAg-
positive donors into sterile un-anticoagulated bottles
and centrifuged. The sera were separated into other
sterile bottles and stored at -20°C. Sera were tested for
HBe antigen and HBcore IgG and IgM antibodies by
the enzyme linked immunosorbent assay (ELISA). The
hepatitis B-specific HBe antigen, HBcore IgG and IgM
were studied by commercial DIA.PRO diagnostic Biop-
robes ELISA kit (Italy) following manufacturer’s in-
struction. All specimens were analyzed using the enzyme
immunoassay test. HBe antigen and HBcore IgM were
interpreted as a ratio (S/Co) where S=optical density
(OD) of the sample at 450 nm and Co is the cut off as fol-
lows< 0.9 = negative, 0.9–1.1= equivocal, >1.1 =Positive.
While HBcore IgG was interpreted as a ratio of the cut off
and sample optical density (OD) of 450 nm (Co/S) as fol-
lows; < 0.9=negative, 0.9–1.1= equivocal, >1.1 =Positive.
The controls and calibrators passed the validation check
recommended by the manufacturers of the three kits.
Sample size determination
Most studies in Nigeria reported average seroprevalence
rates of 10% [18-20]. This figure was used to calculate the
sample size for this study using the formula [21] n= z2pq/d2
where Z=1.96 normal deviate representing the 95% confi-
dence limit, d=0.05 as acceptable margin of error, p=
reported seroprevalence 10% (0.1), q which is the prob-
ability of the event not occurring, which will be 1-p = 0.9
to obtain a minimum sample size of 138.22. However, a
sample size of 267 was used to determine the true
seroprevalence.
Statistical assessment
A statistical software package SPSS version 16 was used
for data analysis. The descriptive data were given as
means ± SD. The chi-squared was used for the analytical
assessment. The differences were considered to be statisti-
cally significant when the p value obtained was< 0.05.
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A total of 267 HBsAg positive blood donors were studied.
The mean age was 33.73 ±7.988 years with a minimum
age of 17 years and maximum of 59 years. Majority, 261 of
267 donors (97.8%) were males, while 6 of 267 (2.2%) were
females (Table 1). The donors consisted predominantly of
family replacement donors which number was 237of 267
of donors (88.8%), while 30 of the 267 donors (11.2%) were
voluntary donors. Only 114 (42.7%) were single and 153 of
267 (57.3%) were married. A total of 265 of 267 (99.3%) of
the donors gave history of having only one sexual partner,
while 1 (0.4%) each had two and three sexual partners. All
the participants were heterosexual and gave no history of
previous sexually transmitted infection. A total of 64 (24%)
of the donors had never had unprotected sex, 190 (71.2%)
occasionally had unprotected sex, and 13(4.9%) frequently
engaged in unprotected sex. Only 11(4.1%) admitted to use
of intravenous drug, 83 of the 267 (31.1%) had previous
history of blood transfusion while 184 (68.9%) gave no pre-
vious history of blood transfusion. Majority of the donors
253(94.8%) gave no previous history of jaundice, while 14
(5.2%) had a previous history of jaundice.
A seroprevalence of 8.2% (22 of 267) HBe Ag- positive
donors was obtained (Table 2), 4 of the 267 (1.5%)
donors were indeterminate while 241(90.3%) tested nega-
tive. Only 27 of the 267 (10.1%) tested positive to IgM
anti-HBcore, 234(87.6%) tested negative, while 6(2.2%)
were indeterminate. A higher percentage of 60.7% (162
of 267) tested positive to IgG anti-HBcore, and 39.3%
(105 of 267) tested negative.
Out of the 22 donors who tested positive to HBeAg, and
4 that were indeterminate, 10 (38.5%) had previous history
















Family replacement 237 88.8%
Total 267 100%blood transfusion p value = 0.666. (Table 3). Only 2(7.7%)
were voluntary blood donors, while 24(92.3%) were re-
placement donors p value = 0.208. Majority 18(69.2%) ad-
mitted to occasional unprotected sex, only 1 (3.8%) always
had unprotected sex, while 7(26.9%) never had unpro-
tected sex. P value = 0.504. A total of 20 (76.9%) of 26 of
these subjects, tested positive to IgG anti-HBcore, while 6
(23.1%) tested negative. Only 4(15.4%) tested positive to
IgM anti-HBcore, majority 21 (80.8%) tested negative,
while 1 (3.8%) was indeterminate.
Almost all 240 of the 241 (99.6%) who tested negative
to HBeAg had one sexual partner, 73 of the 241(30.3%)
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the total number of 267 enrolled for the study, almost
all (28 of 30) voluntary donors (10.4%) tested negative to
HBeAg while 88.6% replacement donors tested negative.
Similarly, out of the 241 who tested negative to HBeAg,
142 of 241(58.9%) tested positive to HBcore IgG and 99
of the 241(41.1%) tested negative.
Discussion
Low seroprevalence rates of HBeAg-positive hepatitis
were reported in various parts of Nigeria. The value of
8.2% obtained in this study is similar to 8.6% reported at
Enugu city, East [18], 10.8% at Ibadan, West [19], and
8.8% at Benin City, South [20].
Chronic hepatitis is characterized by either the presence
or absence of HBeAg. A significant proportion of this study
population (91.8%) was HBeAg- negative. Similarly high
values of 86.4% was obtained in Italy, [22] the Mediterra-
nean, (30–80%) [23] Asia and in the Far East [24]. This
form of chronic HBV HBeAg-negative CHB is common in
areas where infection occurs in early childhood [25].
HBeAg-negative patients harbor HBV variants with a mu-
tation in the core promoter or the pre core region of the
HBV genome therefore affecting production of HBeAg but
not replication [23]. The most frequent variant creates a
stop codon in the precore region which completely
abolishes the production of HBeAg [26]. The proportion of
HBeAg-negative is rising worldwide, with patients with
HBeAg-negative chronic hepatitis developing more active,
advanced, and progressive liver disease. The consequent
severe necro-inflammation is associated with infection in
over 50% of the patients [27]. Chronic HBeAg-negative
hepatitis is usually a late phase in the natural history of
chronic HBV infection, rather than a result of de novo in-
fection with a mutated variant [27].
A seroprevalence of 60.7% of IgG anti-HB core was
obtained amongst the HBsAg positive blood donors in
this study. Practically all HBsAg positive are expected to
be IgG anti-HBc positive. This could be a reflection of
the high false positive rate of the kit used for HBsAg
screening at study centres. A 4th generation ELISA kit
manufactured by Bio-Rads laboratories (France) are
used routinely for HBsAg positive screening amongst
blood donors at both centres. The kit has a high sensi-
tivity and possibly a high false positive rate with the aim
of protecting recipient from infection. While 10.1% had
IgM anti-HBcore which signifies active and recent in-
fection. Sheik et al. had reported a seroprevalence of
10% of IgM anti-HBcore in Pakistan [28]. A 4% sero-
prevalence of IgM anti-HBcore was reported in Italy (a
low prevalence area) amongst HBsAg positive donors
who were chronically infected but 85% of the same
patients tested positive to IgM anti-HBcore when they
were acutely infected [29].A total (consisting of both IgG anti-HBcore and IgM
anti-HBcore) anti HBcore of 16.2% was reported in
Yemen [30], and 13.5% in Korea [31], amongst blood
donors. Antibody to hepatitis B core antigen is the first
to develop, following acute hepatitis B infection, which
appears predominantly as IgM anti-HBc at about 6 weeks
after infection. The antibody typically persists for life ex-
cept resolution of acute hepatitis B virus infection
occurs. However, a significant proportion of hepatitis B
surface antigen negative of the population in high preva-
lence areas like Nigeria, may test positive to anti-HBc,
these individuals are described as having isolated anti-
HBc hepatitis. It is not clear whether patients with iso-
lated hepatitis are infectious; however, HBV DNA has
been detected in the serum of patients with isolated anti-
HBc hepatitis. Antar et al. reported a 7.8% prevalence of
isolated hepatitis amongst Egyptian blood donors, 6.25%
of these patients had detectable serum HBV DNA [32].
The issue of isolated hepatitis brings to forefront the in-
effectiveness of HBsAg screening (which is what is used
in Nigeria) in protecting blood recipients from hepatitis
B infection. It has been suggested that anti-HBc testing
should be combined with HBsAg screening of blood
donors to reduce the risk of HBV infection [33].
This study could not establish a significant association
between chronic hepatitis and previous history of blood
transfusion, and also whether the donor was a voluntary or
replacement donor, or the issue of having unprotected sex-
ual intercourse the three major risk factors of infectivity.
Majority of the individuals in areas with high prevalence of
chronic hepatitis B infection like Nigeria where carrier rates
are >5% are infected at birth or during early childhood
[34]. Hence majority of the patients could have acquired
the infection at birth or early childhood.
Hepatitis B vaccination for newborn babies was intro-
duced to Nigeria about ten years ago as part of the
expanded programme on immunization, the vaccination
offers >95% protection against the development of chronic
hepatitis infection [34]. None of the blood donors used in
this study could have benefitted from the hepatitis B vac-
cination, because the minimum age of the blood donors in
the study was 17 years.Conclusion
A low seroprevalence rate of 8.2% HBeAg-positive and high
91.8% HBeAg-negative chronic hepatitis and a relatively
high IgG anti-HBcore and IgM anti-HBcore is seen the
Nigeria.
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